drugset / Trial / NCT01408888

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

NCT01408888

Phase 1 Completed 29 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together. The duration of participation in this study is expected to be approximately 61 days. The study requires 2 clinic confinements (one of 2 nights and one of 19 nights duration). The study involves 3 injections, subcutaneous, of 1.5 milligrams (mg) LY2189265 and 18 daily doses of 100 mg sitagliptin tablets administered orally.

Timeline

Start
2011-08
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 1.5 mg Subcutaneous
Subject Sitagliptin Small molecule 100 mg Oral